artesunate suppository / Frantz Viral Therap - LARVOL DELTA

anal HSIL HIV-: Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL (clinicaltrials.gov) - P2 | N=17 | Active, not recruiting | Sponsor: Frantz Viral Therapeutics, LLC | Trial completion date: Aug 2024 ➔ Dec 2024

Trial completion date • Anal Carcinoma • Human Immunodeficiency Virus • Human Papillomavirus Infection • Infectious Disease • Oncology

anal HSIL HIV-: Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL (clinicaltrials.gov) - P2 | N=17 | Active, not recruiting | Sponsor: Frantz Viral Therapeutics, LLC | Recruiting ➔ Active, not recruiting | N=48 ➔ 17

Enrollment change • Enrollment closed • Anal Carcinoma • Human Immunodeficiency Virus • Human Papillomavirus Infection • Infectious Disease • Oncology

anal HSIL HIV-: Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL (clinicaltrials.gov) - P2 | N=48 | Recruiting | Sponsor: Frantz Viral Therapeutics, LLC | Not yet recruiting ➔ Recruiting | Trial completion date: Apr 2024 ➔ Aug 2024 | Trial primary completion date: Oct 2023 ➔ Feb 2024

Enrollment open • Trial completion date • Trial primary completion date • Anal Carcinoma • Human Immunodeficiency Virus • Infectious Disease • Oncology

anal HSIL HIV-: Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: Frantz Viral Therapeutics, LLC

New P2 trial • Anal Carcinoma • Human Immunodeficiency Virus • Infectious Disease • Oncology

ART-AIN: Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3) (clinicaltrials.gov) - P1; N=18; Completed; Sponsor: Johns Hopkins University; Active, not recruiting ➔ Completed

Clinical • Trial completion • Oncology

ART-AIN: Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3) (clinicaltrials.gov) - P1; N=18; Active, not recruiting; Sponsor: Johns Hopkins University; Trial primary completion date: Apr 2021 ➔ Oct 2021

Clinical • Trial primary completion date • Oncology

ART-AIN: Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3) (clinicaltrials.gov) - P1; N=18; Active, not recruiting; Sponsor: Johns Hopkins University; Recruiting ➔ Active, not recruiting; Trial completion date: Jul 2021 ➔ Oct 2021

Clinical • Enrollment closed • Trial completion date • Oncology

ART-AIN: Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3) (clinicaltrials.gov) - P1; N=18; Recruiting; Sponsor: Johns Hopkins University; Trial completion date: Dec 2020 ➔ Jul 2021; Trial primary completion date: Sep 2020 ➔ Mar 2021

Clinical • Trial completion date • Trial primary completion date • Oncology

ART-AIN: Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3) (clinicaltrials.gov) - P1; N=18; Recruiting; Sponsor: Johns Hopkins University; Trial completion date: Mar 2020 ➔ Dec 2020; Trial primary completion date: Dec 2019 ➔ Sep 2020

Clinical • Trial completion date • Trial primary completion date

Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3) (clinicaltrials.gov) - P1; N=29; Completed; Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Active, not recruiting ➔ Completed

Clinical • Trial completion

ART-AIN: Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3) (clinicaltrials.gov) - P1; N=18; Recruiting; Sponsor: Johns Hopkins University; Trial primary completion date: Jul 2019 ➔ Dec 2019

Clinical • Trial primary completion date